Journal ArticleDOI
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
Augustus S. Rose,Jan W. Kuzma,John F. Kurtzke,Norman S. Namerow,William A. Sibley,Wallace W. Tourtellotte +5 more
About:
This article is published in Neurology.The article was published on 1970-05-01. It has received 252 citations till now. The article focuses on the topics: Placebo & Clinical trial.read more
Citations
More filters
Journal ArticleDOI
Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials
Jessica Costello,Annete Njue,Matthew Lyall,Anne Heyes,Nancy Mahler,Michael Philbin,Tara Nazareth +6 more
TL;DR: RCTs indicate IVMP and RCI are efficacious and well tolerated treatments for MS relapse, and contemporary evidence generation for all relapse treatments of interest, across efficacy, safety, and QOL outcomes is still needed.
Journal ArticleDOI
Methodology tor analyzing clinical neurological data: ACTH in multiple sclerosis
TL;DR: The quantitative neurological data have been re‐evaluated using a transformation of the data which express patient scores in terms of a percentage of age‐ and sex‐matched normal function followed by a reduction of theData into composite neurological functions vs time.
Journal ArticleDOI
Blood lymphocyte subpopulations show characteristic changes during ACTH therapy in acute exacerbations of multiple sclerosis.
TL;DR: A significant transitory decrease of the absolute and relative T‐cell proportions with a minimum around the tenth day of treatment is observed, accompanied by inverse changes of the null‐cell numbers.
Journal ArticleDOI
Relation between EEG and disability scores in multiple sclerosis
TL;DR: Significant improvement in the clinical state of the patient and a marked increase of the mean alpha frequency in the parietooccipital region could be demonstrated after short intensive immunosuppressive therapy.
Journal ArticleDOI
Therapeutic advances: beta-interferon for multiple sclerosis.
TL;DR: The high cost of betainterferon, the distressing nature of MS and the small benefit demonstrated in clinical trials mean that purchasers and clinicians will face hard decisions in managing the introduction of these drugs.
Related Papers (5)
A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis
Roy W. Beck,Patricia A. Cleary,Malcolm M. Anderson,John L. Keltner,William T. Shults,David I. Kaufman,Edward G. Buckley,James J. Corbett,Mark J. Kupersmith,Neil R. Miller,Peter J. Savino,John Guy,Jonathan D. Trobe,John A. McCrary,Craig H. Smith,Georgia A. Chrousos,H. Stanley Thompson,Barrett Katz,Michael C. Brodsky,James Goodwin,Constance W. Atwell +20 more